MARKET

CTLT

CTLT

Catalent Inc
NYSE
52.25
+0.02
+0.04%
Closed 19:49 12/02 EST
OPEN
51.59
PREV CLOSE
52.23
HIGH
53.06
LOW
51.19
VOLUME
4.21M
TURNOVER
--
52 WEEK HIGH
130.97
52 WEEK LOW
40.69
MARKET CAP
9.40B
P/E (TTM)
22.35
1D
5D
1M
3M
1Y
5Y
Biotech firm Catalent to shut down Webster facility in 2023, cut jobs
The company said it would offer severance and job transition support to the affected employees, and cited economic stresses as a factor in shutting down the plant
American City Business Journals · 3d ago
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, November 29, 2022: DIS, BA, MRVL, CTLT, ONCS
Benzinga · 5d ago
Should You Add Catalent (CTLT) to Your Portfolio for the Long-Term?
Aristotle Capital Boston, LLC, an investment advisor, released its “Small/Mid Cap Equity” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund returned -4.67% net of fees compared to -2.82% return fo...
Insider Monkey · 11/27 01:59
BRIEF-Catalent Inc Unit Entered Into Amendment No. 7 To Amended And Restated Credit Agreement
Reuters · 11/22 22:51
CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day
CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day.
Zacks · 11/16 14:02
Bear Of The Day: Catalent (CTLT)
Earnings estimates have slipped for this stock following the most recent earnings miss.
Zacks · 11/16 12:13
Here’s Why Catalent (CTLT) Underperformed in the Third Quarter
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTMX returned -2.43%, Advisor Class fund A...
Insider Monkey · 11/15 14:52
ClearBridge Investments’ Worst Q3 Performer: Catalent (CTLT)
ClearBridge Investments, an investment management firm, published its “SMID Cap Growth Strategy” third-quarter 2022 investor letter – a copy of which can be downloaded here. During the third quarter, the ClearBridge SMID Cap Growth Strategy underperformed ...
Insider Monkey · 11/11 04:40
More
About CTLT
Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.

Webull offers kinds of Catalent Inc stock information, including NYSE:CTLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTLT stock methods without spending real money on the virtual paper trading platform.